CRISPR Therapeutics Moves Into Off-The-Shelf CAR-T Lead, But Durability Test Awaits
Allogene Remains A Rival Despite Safety Hiatus
Some remain unconvinced on durability, but CRISPR Therapeutics is looking at a second ‘consolidation’ dose and other measures to boost CTX110’s efficacy in a pivotal trial.
You may also be interested in...
Allogene is the frontrunner in the allogeneic CAR-T field but must assess whether or not its therapy could have caused a patient’s unexpected chromosomal abnormality.
The King's College London spin-out has gained £11.5m backing to take its ‘parallel CAR-T’ into the clinic.
An attempt to show efficacy even in younger people with mild COVID-19 symptoms has fallen flat in Phase II, and AT-527 will now lag behind rivals Merck and Pfizer.